These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25525118)

  • 1. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
    Tiede A; Klamroth R; Scharf RE; Trappe RU; Holstein K; Huth-Kühne A; Gottstein S; Geisen U; Schenk J; Scholz U; Schilling K; Neumeister P; Miesbach W; Manner D; Greil R; von Auer C; Krause M; Leimkühler K; Kalus U; Blumtritt JM; Werwitzke S; Budde E; Koch A; Knöbl P
    Blood; 2015 Feb; 125(7):1091-7. PubMed ID: 25525118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study.
    Dobbelstein C; Moschovakis GL; Tiede A
    Ann Hematol; 2020 Sep; 99(9):2105-2112. PubMed ID: 32621181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.
    Tiede A; Hofbauer CJ; Werwitzke S; Knöbl P; Gottstein S; Scharf RE; Heinz J; Groß J; Holstein K; Dobbelstein C; Scheiflinger F; Koch A; Reipert BM
    Blood; 2016 May; 127(19):2289-97. PubMed ID: 26912467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.
    Ogawa Y; Yanagisawa K; Naito C; Uchiumi H; Ishizaki T; Shimizu H; Gohda F; Ieko M; Ichinose A; Handa H
    Int J Hematol; 2020 Apr; 111(4):544-549. PubMed ID: 31939075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
    Goldmann G; Marquardt N; Horneff S; Oldenburg J; Zeitler H
    Atheroscler Suppl; 2015 May; 18():74-9. PubMed ID: 25936308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study.
    Vautier M; de Boysson H; Creveuil C; Repesse Y; Borel-Derlon A; Troussard X; Damaj GL; Bienvenu B; Gautier P; Aouba A
    Medicine (Baltimore); 2016 Nov; 95(48):e5232. PubMed ID: 27902587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.
    Liu Y; Ruan X; Lei P; Shang B; Zhu Z; Chen S; Wang D; Wang R; Li X; Xue F
    Clin Appl Thromb Hemost; 2023; 29():10760296221151165. PubMed ID: 36653966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.
    Mizrahi T; Doyon K; Dubé E; Bonnefoy A; Warner M; Cloutier S; Demers C; Castilloux JF; Rivard GE; St-Louis J
    Haemophilia; 2019 Mar; 25(2):252-257. PubMed ID: 30694571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.
    Tay L; Duncan E; Singhal D; Al-Qunfoidi R; Coghlan D; Jaksic W; Szabo F; McRae S; Lloyd J
    Semin Thromb Hemost; 2009 Nov; 35(8):769-77. PubMed ID: 20169513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.
    Salaj P; Geierová V; Ivanová E; Loužil J; Pohlreichová V; Hrachovinová I; Dulíček P
    Haemophilia; 2020 Jul; 26(4):643-651. PubMed ID: 32590889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acquired hemophilia A with reappearance of inhibitor 10 years after the completion of immunosuppressive therapy].
    Oshida K; Ito T; Shirayama R; Kusuhara K; Sato T; Sakai M
    Rinsho Ketsueki; 2021; 62(3):186-189. PubMed ID: 33828012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
    Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
    Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan.
    Ogawa Y; Yanagisawa K; Uchiumi H; Ishizaki T; Mitsui T; Gouda F; Ieko M; Ichinose A; Nojima Y; Handa H
    Int J Hematol; 2017 Jul; 106(1):82-89. PubMed ID: 28299631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.
    Holstein K; Liu X; Smith A; Knöbl P; Klamroth R; Geisen U; Eichler H; Miesbach W; Tiede A
    Blood; 2020 Jul; 136(3):279-287. PubMed ID: 32268359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).
    Collins P; Baudo F; Knoebl P; Lévesque H; Nemes L; Pellegrini F; Marco P; Tengborn L; Huth-Kühne A;
    Blood; 2012 Jul; 120(1):47-55. PubMed ID: 22517903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and prognostic factors of acquired haemophilia A in Korea.
    Hyun SY; Shin HJ; Yoon SS; Moon JH; Han JJ; Yang DH; Lee WS; Bang SM; Yhim HY; Kim SH; Oh D; Do YR; Park Y; Choi CW; Lee JH; Jang JE; Kim SJ; Hwang DY; Kim JS
    Haemophilia; 2021 Sep; 27(5):e609-e616. PubMed ID: 34156738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.
    Sun B; Xue F; Feng Y; Sun J; Yu Z; Hou M; Zhang J; Zeng X; Zhao Y; Lian S; Huang M; Niu T; Cui Z; Wu J; Yang R
    Br J Haematol; 2019 Dec; 187(5):653-665. PubMed ID: 31372978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.